cardiotomskСибирский журнал клинической и экспериментальной медициныSiberian Journal of Clinical and Experimental Medicine2713-29272713-265XTSU publishing10.29001/2073-8552-2014-29-2-21-27cardiotomsk-73Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESАнтагонисты рецепторов эндотелина в лечении легочной артериальной гипертензии (обзор литературы)Endothelin receptor antagonist in the treatment of pulmonary arterial hypertension (literature review)ИвановСергей НиколаевичIvanovS. N.ivanov7478@rambler.ruВолковаТамара ГеоргиевнаVolkovaT. G.noemail@neicon.ruВолковРэм ВалерьевичVolkovR. V.noemail@neicon.ruХрусталеваЮлия АлександровнаKhrustalevaYu. A.noemail@neicon.ruЕфименкоВалентина ГеннадьевнаEfimenkoV. G.noemail@neicon.ruФГБУ “Новосибирский НИИ патологии кровообращения им. акад. Е.Н. Мешалкина” Минздрава РоссииРоссияFederal State Institution "Novosibirsk Research Institute of Circulation Pathology n.a. аcad. E.N. Meshalkin" of the Ministry of Healthcare of the Russian FederationRussian FederationФГБУ "Новосибирский НИИ патологии кровообращения им. акад. Е.Н. Мешалкина" Минздрава РоссииРоссияFederal State Institution "Novosibirsk Research Institute of Circulation Pathology n.a. аcad. E.N. Meshalkin" of the Ministry of Healthcare of the Russian FederationRussian FederationГосударственная Новосибирская областная клиническая больницаРоссияNovosibirsk State Regional HospitalRussian Federation2014060920162922127Copyright © Иванов С.Н., Волкова Т.Г., Волков Р.В., Хрусталева Ю.А., Ефименко В.Г., 20162016Иванов С.Н., Волкова Т.Г., Волков Р.В., Хрусталева Ю.А., Ефименко В.Г.Ivanov S.N., Volkova T.G., Volkov R.V., Khrustaleva Y.A., Efimenko V.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.sibjcem.ru/jour/article/view/73

В аналитической статье представлен обзор литературы по использованию антагонистов рецепторов эндотелина в лечении легочной артериальной гипертензии (ЛАГ). Обсуждаются основные препараты, широко используемые в практике, - это бозентан (траклир) и амбризентан. В настоящее время в России зарегистрированы оба препарата этой группы. В статье приводятся основные клинические исследования по применению антагонистов рецепторов эндотелина.

This analytical article provides a review of the literature for using the endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. The authors discuss the use of two main drugs widely used in clinical practice: bosentan (Tracleer) and ambrisentan. Both these drugs have been registered in the Russian Federation. The article presents findings of the main clinical trials of endothelin receptor antagonists.

легочная артериальная гипертензиябозентан (траклир)амбризентанpulmonary arterial hypertensionbosentan (Tracleer)ambrisentanReferencesMoledina S., Hislop A., Foster H. et al. Childhood idiopathic pulmonary arterial hypertension: a national cohort study // Heart. - 2010. - Vol. 96, Issue 17. - P. 1401-1406.Moledina S., Hislop A., Foster H. et al. Childhood idiopathic pulmonary arterial hypertension: a national cohort study // Heart. - 2010. - Vol. 96, Issue 17. - P. 1401-1406.Krum H. New and emerging pharmacologic strategies in the management of chronic heart failure // Clin. Cardiol. - 2000. -Vol. 23(10). - P. 724-730.Krum H. New and emerging pharmacologic strategies in the management of chronic heart failure // Clin. Cardiol. - 2000. -Vol. 23(10). - P. 724-730.Humbert M., Sitbon O., Chaouat A. et al. Pulmonary arterial hypertension in France: results from a national registry // Am. J. Respir. Crit. Care Med. - 2006. - Vol. 173(9). - P. 1023-1030.Humbert M., Sitbon O., Chaouat A. et al. Pulmonary arterial hypertension in France: results from a national registry // Am. J. Respir. Crit. Care Med. - 2006. - Vol. 173(9). - P. 1023-1030.Galie N., Manes A., Branzi A. The endothelin system in pulmonary arterial hypertension // Cardiovasc. Res. - 2004. - Vol. 61. -P. 227-237.Galie N., Manes A., Branzi A. The endothelin system in pulmonary arterial hypertension // Cardiovasc. Res. - 2004. - Vol. 61. -P. 227-237.Nootens M., Kaufmann E., Rector T. et al. Neurohormonal activation in subjects with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels // J. Am. Coll. Cardiol. - 1995. - Vol. 26. -P. 1581-1585.Nootens M., Kaufmann E., Rector T. et al. Neurohormonal activation in subjects with right ventricular failure from pulmonary hypertension: relation to hemodynamic variables and endothelin levels // J. Am. Coll. Cardiol. - 1995. - Vol. 26. -P. 1581-1585.Galie N., Hoeper M.M., Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension // Eur. Respir. J. - 2009. - Vol. 34. - P. 1219-1263.Galie N., Hoeper M.M., Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension // Eur. Respir. J. - 2009. - Vol. 34. - P. 1219-1263.Dimopoulos K., Inuzuka R., Goletto S. et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension // Circulation. - 2010. - Vol. 121(1). - P. 20-25.Dimopoulos K., Inuzuka R., Goletto S. et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension // Circulation. - 2010. - Vol. 121(1). - P. 20-25.Архипова О.А., Мартынюк Т.В., Лазуткина В.К. и др. Применение неселективного антагониста рецепторов эндотелина при идиопатической легочной гипертензии // Тер. архив. - 2010. - № 11. - С. 1-4.Архипова О.А., Мартынюк Т.В., Лазуткина В.К. и др. Применение неселективного антагониста рецепторов эндотелина при идиопатической легочной гипертензии // Тер. архив. - 2010. - № 11. - С. 1-4.Peacock A., Keogh A., Humbert M. Endpoints in pulmonary arterial hypertension: the role of clinical worsening // Cur. Opin. Pulm. Med. - 2010. - Suppl. 1. - P. S1-S9.Peacock A., Keogh A., Humbert M. Endpoints in pulmonary arterial hypertension: the role of clinical worsening // Cur. Opin. Pulm. Med. - 2010. - Suppl. 1. - P. S1-S9.Nickel N., Golpon H., Greer M. et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension // Eur. Respir. J. - 2012. - Vol. 39. -P. 589-596.Nickel N., Golpon H., Greer M. et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension // Eur. Respir. J. - 2012. - Vol. 39. -P. 589-596.Channick R.N., Simonneau G., Sitbon O. et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study // Lancet. - 2001. - Vol. 358(9288). - P. 1119-1123.Channick R.N., Simonneau G., Sitbon O. et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study // Lancet. - 2001. - Vol. 358(9288). - P. 1119-1123.Rubin L.J., Badesch D.B., Barst R.J. et al. Bosentan therapy for pulmonary arterial hypertension // N. Engl. J. Med. - 2002. -Vol. 346(12). - P. 896-903.Rubin L.J., Badesch D.B., Barst R.J. et al. Bosentan therapy for pulmonary arterial hypertension // N. Engl. J. Med. - 2002. -Vol. 346(12). - P. 896-903.Ahmadi-Simab K., Lamprecht P., Hellmisch B. et al. Treatment of pulmonary arterial hypertension (PAH) with oral endothelin-receptor antagonist bosentan in systemic sclerosis: BREATHE-1 trial and clinical experience // Rheumatol. - 2004. - Vol. 63(6). - P. 495-497.Ahmadi-Simab K., Lamprecht P., Hellmisch B. et al. Treatment of pulmonary arterial hypertension (PAH) with oral endothelin-receptor antagonist bosentan in systemic sclerosis: BREATHE-1 trial and clinical experience // Rheumatol. - 2004. - Vol. 63(6). - P. 495-497.Channick R.N., Simonneau G., Sitbon O. et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study // Lancet. - 2001. - Vol. 358(9288). - P. 1119-1123.Channick R.N., Simonneau G., Sitbon O. et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study // Lancet. - 2001. - Vol. 358(9288). - P. 1119-1123.Galiè N., Rubin L.J., Hoeper M. et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial // Lancet. - 2008, Jun. 21. - Vol. 371(9630). - P. 2093-2100.Galiè N., Rubin L.J., Hoeper M. et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial // Lancet. - 2008, Jun. 21. - Vol. 371(9630). - P. 2093-2100.Denton C.P., Humbert M., Rubin L. et al. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions // Ann. Rheum. Dis. - 2006, Oct. -Vol. 65(10). - P. 1336-1340.Denton C.P., Humbert M., Rubin L. et al. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions // Ann. Rheum. Dis. - 2006, Oct. -Vol. 65(10). - P. 1336-1340.McLaughlin V.V. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan // Eur. J. Clin. Invest. - 2006, Sep. - Vol. 36, Suppl. 3. - P. 10-15.McLaughlin V.V. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan // Eur. J. Clin. Invest. - 2006, Sep. - Vol. 36, Suppl. 3. - P. 10-15.Bonderman D., Nowotny R., Skoro-Sajer N. et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension // Chest. - 2005, Oct. - Vol. 128(4) - P. 2599-2603.Bonderman D., Nowotny R., Skoro-Sajer N. et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension // Chest. - 2005, Oct. - Vol. 128(4) - P. 2599-2603.Горбатых Ю.Н., Ленько Е.В., Иванов С.Н. и др. Выбор алгоритма ведения взрослых больных с врожденными дефектами перегородок сердца, открытым артериальным протоком // Патология кровообращения и кардиохирургия. - 2011. - № 1. - С. 84-92.Горбатых Ю.Н., Ленько Е.В., Иванов С.Н. и др. Выбор алгоритма ведения взрослых больных с врожденными дефектами перегородок сердца, открытым артериальным протоком // Патология кровообращения и кардиохирургия. - 2011. - № 1. - С. 84-92.Galie N., Beghetti M., Gatzoulis M.A. et al. Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebocontrolled study // Circulation. - 2006, Jul. 4. - Vol. 114(1). -P. 48-54.Galie N., Beghetti M., Gatzoulis M.A. et al. Bosentan Randomized Trial of Endothelin Antagonist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebocontrolled study // Circulation. - 2006, Jul. 4. - Vol. 114(1). -P. 48-54.Forfia P.R., Fisher M.R., Mathai S.C. et al. Tricuspid annular displacement predicts survival in pulmonary hypertension // Am. J. Respir. Crit. Care Med. - 2006, Nov. 1. - Vol. 174(9). -P. 1034-1041.Forfia P.R., Fisher M.R., Mathai S.C. et al. Tricuspid annular displacement predicts survival in pulmonary hypertension // Am. J. Respir. Crit. Care Med. - 2006, Nov. 1. - Vol. 174(9). -P. 1034-1041.Dimopoulos K., Inuzuka R., Goletto S. et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension // Circulation. - 2010, Jan. 5. - Vol. 121(1). - P. 20-25.Dimopoulos K., Inuzuka R., Goletto S. et al. Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension // Circulation. - 2010, Jan. 5. - Vol. 121(1). - P. 20-25.Galie N., Rubin L.J., Hoeper M.M. et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomized controlled trial // Lancet. - 2008. - Vol. 371. - P. 2098-2100.Galie N., Rubin L.J., Hoeper M.M. et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomized controlled trial // Lancet. - 2008. - Vol. 371. - P. 2098-2100.Gan C.T., McCann G.P., Marcus J.T. et al. NTproBNP reflects right ventricular structure and function in pulmonary hypertension // Eur. Respir. J. - 2006, Dec. - Vol. 28(6). - P. 1190-1194.Gan C.T., McCann G.P., Marcus J.T. et al. NTproBNP reflects right ventricular structure and function in pulmonary hypertension // Eur. Respir. J. - 2006, Dec. - Vol. 28(6). - P. 1190-1194.Barst R.J., Ivy D., Dingemanse J. et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension // Clin. Pharmacol. Ther. - 2003. - Vol. 73(4). - P. 810-815.Barst R.J., Ivy D., Dingemanse J. et al. Pharmacokinetics, safety, and efficacy of bosentan in pediatric patients with pulmonary arterial hypertension // Clin. Pharmacol. Ther. - 2003. - Vol. 73(4). - P. 810-815.Akagi S., Matsubara H., Miyaji K. Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol // Circ. J. - 2008, Jul. - Vol. 72(7). - P. 1142-1146.Akagi S., Matsubara H., Miyaji K. Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol // Circ. J. - 2008, Jul. - Vol. 72(7). - P. 1142-1146.Иванов С.Н., Горбатых Ю.Н., Волкова Т.Г. и др. Опыт диагностики и лечения детей с легочной артериальной гипертензией// Оренбургский медицинский журнал. - 2013. - Т. 1, № 3. - С. 49-50.Иванов С.Н., Горбатых Ю.Н., Волкова Т.Г. и др. Опыт диагностики и лечения детей с легочной артериальной гипертензией// Оренбургский медицинский журнал. - 2013. - Т. 1, № 3. - С. 49-50.Sitbon O., Gressin V., Speich R. et al. Haemodynamic and clinical improvement with bosentan in patients with pulmonary arterial hypertension asscociated with HIV infection // European Society of Cardiology Congress. - Vienna, Austria, 30 August -3 Sept. 2003. - Abstract No. 2568.Sitbon O., Gressin V., Speich R. et al. Haemodynamic and clinical improvement with bosentan in patients with pulmonary arterial hypertension asscociated with HIV infection // European Society of Cardiology Congress. - Vienna, Austria, 30 August -3 Sept. 2003. - Abstract No. 2568.ACCF/AHA 2009. Expert Consensus Document on Pulmonary Hypertension A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association // Circulation. - 2009. -Vol. 119. - P. 2250-2294.ACCF/AHA 2009. Expert Consensus Document on Pulmonary Hypertension A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association // Circulation. - 2009. -Vol. 119. - P. 2250-2294.Berger R., Beghetti M., Humpl T. et al. Clinical features of paediatric pulmonary hypertension: a registry study // Lancet. - 2012. - Vol. 379. - P. 537-546.Berger R., Beghetti M., Humpl T. et al. Clinical features of paediatric pulmonary hypertension: a registry study // Lancet. - 2012. - Vol. 379. - P. 537-546.Мартынюк Т.В. Первые Российские рекомендации по диагностике и лечению легочной гипертензии // Актуальные вопросы болезней сердца и сосудов. - 2007. - № 4. - С. 45-51.Мартынюк Т.В. Первые Российские рекомендации по диагностике и лечению легочной гипертензии // Актуальные вопросы болезней сердца и сосудов. - 2007. - № 4. - С. 45-51.Диагностика и лечение легочной гипертензии // Российские рекомендации. - М., 2007. - 32 с.Диагностика и лечение легочной гипертензии // Российские рекомендации. - М., 2007. - 32 с.Humbert M., Sitbon O., Simonneau G. Treatment of pulmonary hypertension // N. Eng. J. Med. - 2004. - Vol. 351. - P. 1425-1436.Humbert M., Sitbon O., Simonneau G. Treatment of pulmonary hypertension // N. Eng. J. Med. - 2004. - Vol. 351. - P. 1425-1436.Rubin L.J., Badesch D.B., Barst R.J. et al. Bosentan therapy for pulmonary arterial hypertension // N. Engl. J. Med. - 2002, Mar. 21 - Vol. 346(12). - P. 896-903.Rubin L.J., Badesch D.B., Barst R.J. et al. Bosentan therapy for pulmonary arterial hypertension // N. Engl. J. Med. - 2002, Mar. 21 - Vol. 346(12). - P. 896-903.Мартынюк Т.В., Коносова И.Д., Чазова И.Е. Современные подходы к медикаментозному лечению легочной гипертензии // Consilium Medicum - 2003. - Т. 5, № 5 - С. 293-300.Мартынюк Т.В., Коносова И.Д., Чазова И.Е. Современные подходы к медикаментозному лечению легочной гипертензии // Consilium Medicum - 2003. - Т. 5, № 5 - С. 293-300.Suntharalingam J., Hodgkins D., Cafferty F.H. et al. Does rapid dose titration affect the hepatic safety profile of Bosentan? // Vascular Pharmacology. - 2006, Jun. - Vol. 44(6). - P. 508-512.Suntharalingam J., Hodgkins D., Cafferty F.H. et al. Does rapid dose titration affect the hepatic safety profile of Bosentan? // Vascular Pharmacology. - 2006, Jun. - Vol. 44(6). - P. 508-512.Barst R.J., Langleben D., Badesch D. et al. STRIDE-2 Study Group. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan // J. Am. Coll. Cardiol. - 2006, May 16. - Vol. 47(10). - P. 2049-2056.Barst R.J., Langleben D., Badesch D. et al. STRIDE-2 Study Group. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan // J. Am. Coll. Cardiol. - 2006, May 16. - Vol. 47(10). - P. 2049-2056.Benza R.L., Barst R.J., Galie N. et al. Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival // Chest. - 2008, Oct. - Vol. 134(4). - P. 775-782.Benza R.L., Barst R.J., Galie N. et al. Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival // Chest. - 2008, Oct. - Vol. 134(4). - P. 775-782.McGoon M.D., Frost A.E., Oudiz R.J. et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities // Chest. - 2009, Jan. - Vol. 135(1). - P. 122-129.McGoon M.D., Frost A.E., Oudiz R.J. et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities // Chest. - 2009, Jan. - Vol. 135(1). - P. 122-129.Galffl N., Olschewski H., Oudiz R.J. et al. Ambrisentan in pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2 // Circulation. - 2008, Jun. 10. - Vol. 117(23). - P. 3010-3019.Galffl N., Olschewski H., Oudiz R.J. et al. Ambrisentan in pulmonary Arterial Hypertension, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Studies (ARIES) Group. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2 // Circulation. - 2008, Jun. 10. - Vol. 117(23). - P. 3010-3019.Oudiz R.J., Galie N., Olschewski H. et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension // J. Am. Coll. Cardiol. - 2009. - Vol. 54. - P. 1971-1981.Oudiz R.J., Galie N., Olschewski H. et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension // J. Am. Coll. Cardiol. - 2009. - Vol. 54. - P. 1971-1981.Badesch D.B., Feldman J., Keogh A. et al. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension // Cardiovasc. Ther. - 2012. - Vol. 30. - P. 93-99.Badesch D.B., Feldman J., Keogh A. et al. ARIES-3: ambrisentan therapy in a diverse population of patients with pulmonary hypertension // Cardiovasc. Ther. - 2012. - Vol. 30. - P. 93-99.Beghetti M., Hoeper M.M., Kiely D.G. et al. Safety experience with bosentan in 146 children 2-11 years with pulmonary arterial hypertension: results from the European post-marketing surveillance program // Pediatr. Res. - 2008. - Vol. 64(2). -P. 200-204.Beghetti M., Hoeper M.M., Kiely D.G. et al. Safety experience with bosentan in 146 children 2-11 years with pulmonary arterial hypertension: results from the European post-marketing surveillance program // Pediatr. Res. - 2008. - Vol. 64(2). -P. 200-204.

The authors declare that there are no conflicts of interest present.